Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $146,558.43 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Jeffrey Farrow sold 2,133 shares of Tarsus Pharmaceuticals stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $68.71, for a total value of $146,558.43. Following the sale, the insider owned 45,502 shares of the company’s stock, valued at approximately $3,126,442.42. This trade represents a 4.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Tarsus Pharmaceuticals Trading Down 3.4%

NASDAQ TARS opened at $64.51 on Friday. The stock has a market cap of $2.75 billion, a PE ratio of -39.82 and a beta of 0.55. Tarsus Pharmaceuticals, Inc. has a 12 month low of $38.51 and a 12 month high of $85.25. The company’s 50-day moving average price is $69.12 and its 200-day moving average price is $70.30. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $151.67 million for the quarter, compared to the consensus estimate of $144.56 million. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. Equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TARS has been the subject of a number of research reports. Oppenheimer boosted their price target on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Lifesci Capital upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 16th. Barclays started coverage on Tarsus Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $100.00 target price for the company. The Goldman Sachs Group reiterated a “neutral” rating and issued a $68.00 target price on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Finally, Zacks Research downgraded Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.83.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. TimesSquare Capital Management LLC purchased a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter valued at approximately $15,898,000. Jennison Associates LLC boosted its stake in Tarsus Pharmaceuticals by 5.5% in the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock worth $154,790,000 after purchasing an additional 136,582 shares in the last quarter. TFG Asset Management GP Ltd grew its position in Tarsus Pharmaceuticals by 40.1% during the 2nd quarter. TFG Asset Management GP Ltd now owns 250,000 shares of the company’s stock worth $10,128,000 after purchasing an additional 71,530 shares during the last quarter. Capricorn Fund Managers Ltd acquired a new position in Tarsus Pharmaceuticals during the 3rd quarter valued at approximately $14,264,000. Finally, Jump Financial LLC increased its stake in Tarsus Pharmaceuticals by 385.9% during the 2nd quarter. Jump Financial LLC now owns 237,117 shares of the company’s stock valued at $9,606,000 after purchasing an additional 188,317 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals News Summary

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published narrower FY‑2026 and quarterly EPS losses (they now model materially smaller losses vs. consensus), supporting a more constructive recovery thesis for the name. Lifesci Capital report
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s bullish view improves outlook but is not yet unanimous across analysts. Analyst consensus
• Neutral Sentiment: Last reported quarter: slight EPS miss (reported ($0.20) vs. ($0.19) est.) but revenue beat — fundamentals are mixed and future price action depends on clinical/launch catalysts and execution. Quarterly results
• Neutral Sentiment: High institutional ownership (~90%) concentrates the float — can stabilize but also amplify moves if large holders or insiders trade. Ownership details
• Negative Sentiment: Clustered insider selling across Mar 16–19: CEO Bobak Azamian sold multiple tranches (totaling ~34,600 shares across Mar 17–19 at ~$67–$69), Director William J. Link sold 12,500 shares, and several other senior officers trimmed positions — large, concentrated insider sales often create short‑term downward pressure and raise questions about timing/intent. Insider sales roundup
• Negative Sentiment: Multiple SEC Form 4s disclose the CEO’s and other officers’ sales (detailed fills and dates are available in the filings), which investors may view as meaningful liquidity events rather than routine small trades. SEC Form 4 (example)

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.